In clinical trials, “clinical holds” are imposed by the FDA when toxicities emerge that are unexpected, either new toxicities that have not been seen before, (or were not anticipated) or increased severity of known or anticipated side effects.  The hold allows the FDA to assess the data, demand more data from the sponsoring companies, and make appropriate changes in the study protocol… Continue reading →